Lv5
845 积分 2021-03-22 加入
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
23天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
23天前
已完结
晚期乳腺癌CDK4/6抑制剂一线治疗挑战及进展后策略
30天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
3个月前
已完结
基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究
6个月前
已完结
中国前列腺癌筛查研究报告（白皮书）
6个月前
已完结
恶性肿瘤骨转移及骨相关疾病临床诊疗中国专家共识
6个月前
已完结
皖公网安备34019202002308
